Evommune to present Phase 2a EVO301 data at 2026 dermatology congress

Sep 23, 2026 20:05 (30d ago)

Verifying

Evommune announced a late-breaker presentation covering Phase 2a EVO301 data.
EVO301 is being studied in atopic dermatitis.
The presentation is scheduled for the European Academy of Dermatology & Venereology 2026 Congress.

The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.